Advanced Solutions
for Advanced Pathology
SOX-11 (MRQ-58)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
44388 SOX-11 RTU M (MRQ-58)
7 ml Ready To Use
44795 SOX-11 0,1 M (MRQ-58)
100 µl liquid Concentrated
44796 SOX-11 1 M (MRQ-58)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Mantle cell lymphoma, Normal Tonsil
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
Product Description
Mantle cell lymphoma (MCL) accounts for 5% to 10% of mature B-cell neoplasms and is an aggressive disease genetically characterized by
overexpression of cyclin D1 (CCND1), an important regulator of the G1/S phase of the cell cycle, due to the specific translocation t(11;14)
(q13;q32). Cyclin D1 overexpression is the hallmark of MCL. However, approximately 5%-10% of MCLs lack cyclin D1 expression and may be
misdiagnosed by overreliance on cyclin D1 IHC. Recently, SOX-11 protein expression in MCL has been investigated by immunohistochemistry.
Two studies have evaluated SOX-11 expression in MCL and found strong nuclear expression of SOX-11 in almost all cyclin D1-positive MCL
(93%-100%). In all 13 cases of cyclin D1-negative MCL, SOX-11 was strongly expressed. The authors also found that blastoid variant of MCL
can be differentiated from CD5+ diffuse large B cell lymphoma, which was negative for SOX-11. In summary, nuclear protein expression of
SOX-11 is highly associated with cyclin D1-positive and negative MCL. The detection of this transcription factor is a useful biomarker for
identifying true cyclin D1-negative MCL. SOX-11 IHC is of value in further defining pathologic features of CD5+ DLBCL. Routine use of SOX-11
in cases of suspected CD5+ DLBCL might help identify additional cases of cyclin D1-negative blastoid MCL. SOX-11 can also be detected in
some BL, LBL and T-PLL, although the different morphological and phenotypic features of these malignancies allow differentiation from cyclin
D1-negative MCL.
Neoplasm
SOX-11
CD20
CD5
CD10
CD23
Cyclin D1
MCL
+
+
+
-
-
+
FL
-
+
-
+
-
-
SLL/CLL
-
+
+
-
+
-
MZL
-
+
-
-
-
-
LBL
+
+
-
+/-
-
-
BL
-/+
+
-
-
-
-
CD5+ DLBCL
-
+
+
+
-
-
Blastoid Variant MCL
+
+
+
-
-
+
Reference
1. Salaverria I, et al. Haematologica 2006; 91:11-6.
2. Fu K, et al. Blood 2005; 106:4315-21.
3. Katzenberger T, et al. Br J Haematol. 2008; 142:538-50.
4. Mozos A, et al. Haematologica. 2009; 94:1555-1562.
5. Wlodarska I, et al. Blood 2008; 111:5683-90.
6. Hargrave M, et al. Dev Dyn. 1997; 210:79-86.
7. Lee CJ, et al. J Neurooncol. 2002; 57:201-14.
8. Weigle B, et al. Oncol Rep. 2005; 13:139-44.
219
